Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer
- Details
- Category: Business
![Insilico Medicine Insilico Medicine](/images/logo/insilico.png)
U.S. FDA approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Bayer launches unit to develop new precision health consumer products
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI
- Details
- Category: Business
![Insilico Medicine Insilico Medicine](/images/logo/insilico.png)
ENPP1 is an ecto-nucleotide pyrophosphatase that plays an important role in purinergic signaling that regulates immune, cardiovascular, neurological, and hematological system functions.
FDA Advisory Committee votes in support of approval for Pfizer's vaccine candidate to help prevent RSV in infants through maternal immunization
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Thermo Fisher Scientific & Pfizer partner to expand localized access to next generation sequencing-based testing for cancer patients in international markets
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
More Pharma News ...
- Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
- Bayer opens first Co.Lab Life science incubator in Cambridge
- Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems
- U.S. FDA approves PREVNAR 20®, Pfizer's 20-valent pneumococcal conjugate vaccine for infants and children
- GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
- Update to contractual arrangements between AstraZeneca, Swedish Orphan Biovitrum AB and Sanofi
- FDA accepts Pfizer's Supplemental New Drug Applications for BRAFTOVI + MEKTOVI